日本人2型糖尿病患者を対象としたチルゼパチド（LY3298176）の研究

基本情報

NCT ID

NCT03322631

ステータス

完了

試験のフェーズ

第1相

試験タイプ

介入

目標被験者数

48

治験依頼者名

Eli Lilly and Company

概要

The purposes of this study are to determine: * The safety of tirzepatide and any side effects that might be associated with it. * How much tirzepatide gets into the bloodstream and how long it takes the body to remove it. * How tirzepatide affects the levels of blood sugar. This study includes eight weekly doses of tirzepatide or placebo given as subcutaneous (SC) injections just under the skin. The study will last about 16 weeks (total), including screening and follow-up. This study is for research purposes only and is not intended to treat any medical conditions.

対象疾患

介入

依頼者（Sponsor）